-
Mashup Score: 0Tesla Camera Scandal is the Latest Lesson in Dangers of Letting Companies Record You | ACLU - 2 year(s) ago
Whether for AI training purposes or simple voyeurism, this abuse of privacy is shocking but unsurprising.
Source: American Civil Liberties UnionCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
AbstractThe success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies propelled the field of synthetic immunology and raised hopes to treat solid tumors in a similar fashion. Antigen escape and the paucity of tumor-restricted CAR targets are recognized challenges to fulfilling this prospect. Recent advances in CAR T cell engineering extend the toolbox of chimeric receptors…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating @MSKCancerCenter @Michel_Sadelain https://t.co/7V9Lo75gA0
-
-
Mashup Score: 7Press Releases | Kite Pharma - 2 year(s) ago
Find recent Kite press releases here.
Source: www.kitepharma.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Axi-Cel Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma - ZUMA7 @KitePharma #CARTcells #lymsm https://t.co/JKyDm56taK
-
-
Mashup Score: 8Bone Marrow Transplantation Fellowship - 2 year(s) ago
The adult hematopoietic stem cell transplantation fellowship program is a one-year program designed to prepare physicians for academic careers in stem cell transplantation, including experience with clinical research.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Seeking advanced training in Stem cell Transplantation or Cellular Therapy, Apply to our @MSKCancerCenter Fellowship - @DavidJChungMD #MedEd #BMTsm #TcellRx #CARTcells https://t.co/uFgw3XYNXZ
-
-
Mashup Score: 7Demographics, motivations, and experiences of participants in transplantation or cellular therapy fellowships - 2 year(s) ago
Recent ASTCT guidelines have sought to establish clinical and research expectations for participants in blood and marrow transplantation (BMT) and cel…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Demographics, motivations, and experiences of participants in transplantation or cellular therapy fellowships @RahulBanerjeeMD @BldCancerDoc @amarkelkar @TheodoraAnagno1 @hemedoc @mikinishitanimd @ASTCT_Journal @ASTCT #bmtsm #TcellRx #MedEd https://t.co/g1xm9eg8b1
-
-
Mashup Score: 1
The American Society for Transplantation and Cellular Therapy (ASTCT) and the National Marrow Donor Program (NMDP) have formed the ACCESS Initiative t…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @JeffAuletta: @vedranr @DrMiguelPerales @CIBMTR @ASTCT_Journal https://t.co/JH5GnSPbLf
-
-
Mashup Score: 10
Use of human leukocyte antigen (HLA)-mismatched donors could enable more patients with ethnically diverse backgrounds to receive allogeneic hematopoie…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Latest @CIBMTR Real-world data showing trends and outcomes by race and ethnicity in alloHCT @JeffAuletta @ASTCT_Journal https://t.co/gTyD1tiXMF
-
-
Mashup Score: 1
Pfizer will buy cancer drugmaker Seagen for $43 billion in one of the industry’s biggest deals in years. The deal, for $229 a share, ends a long-running drama. Pfizer appears to have won by being willing to pay up: In July, Merck was reported to be in talks for a
Source: Endpoints NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @chadinabhan: This is just in. https://t.co/47XCLaQhSi
-
-
Mashup Score: 0CIBMTR Working Committee Training and Leadership (CTL) Program - 2 year(s) ago
We are proud to announce a new CIBMTR Training and Leadership Program specifically for Early Career Investigators (ECI).
Source: cibmtr.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Junior faculty apply for this great opportunity @CIBMTR Working Committee Training and Leadership (CTL) Program #bmtsm #CARTcells https://t.co/c10Z9xGB3q
-
-
Mashup Score: 4Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib - 2 year(s) ago
/PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and the Blood and Marrow Transplant Clinical Trials…
Source: www.prnewswire.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Disappointing to see maintenance gilteritinib didn’t improve outcomes post alloHCT but that’s why it’s important to do Ph3 trials @BMTCTN @AstellasUS #bmtsm #leusm #clinicaltrials https://t.co/upx4eraUIO
-
Tesla Camera Scandal is the Latest Lesson in Dangers of Letting Companies Record You https://t.co/H6cJll7qPx